Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.42 |
| ▸ | TLR2 | O60603 | 4/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10566866 | 0.99 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL10562812 | 0.99 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL2672057 | 0.99 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL3274160 | 0.92 | LPAR1 (0.53) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL667267 | 0.92 | LPAR1 (0.53) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL17291865 | 0.91 | LPAR1 (0.47) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL10563457 | 0.90 | LPAR1 (0.53) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| Ammonia Solution, Strong SCHEMBL6373587 | 0.88 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL2538875 | 0.87 | LPAR1 (0.48) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL1393763 | 0.84 | MAPT (0.50) | LPAR1LPAR3LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | claimed |
| WO-2004087107-A1 | CATIONIC LIPOSOME TARGETING SEBACEOUS GLANDS | TRICHOGENE INC. (KR) | 2004-10-14 | — | — | WO | claimed |
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023054241-A1 | LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUE | 日油株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054243-A1 | LIPID NANOPARTICLES HAVING CELL DIRECTIVITY | 日油株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054242-A1 | LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS | 日油株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2022260678-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220000780-A1 | NANODISCS FOR PREVENTING AND TREATING PATHOGEN INFECTIONS AND METHODS OF USE THEREOF | NASR MAHMOUD (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3484912-B1 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CIRCULARIZED NANODISCS | HARVARD COLLEGE (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3876909-A1 | NANODISCS FOR PREVENTING AND TREATING PATHOGEN INFECTIONS AND METHODS OF USE THEREOF | Nasr, Mahmoud (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20160346219-A1 | PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS | AUTOTELIC LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346220-A1 | PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS | AUTOTELIC LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346221-A1 | PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS | AUTOTELIC LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150079156-A1 | LIPOSOMAL DELIVERY SYSTEM | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2015-03-19 | — | — | US | disclosed |
| EP-2430151-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130898-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2007005672-A2 | TREATMENT AND PREVENTION OF RESPIRATORY DISEASES AND CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2004087107-A1 | CATIONIC LIPOSOME TARGETING SEBACEOUS GLANDS | TRICHOGENE INC. (KR) | 2004-10-14 | — | — | WO | disclosed |
| US-20020052310-A1 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY THE PENN STATE RESEARCH FOUNDATION | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052310-A1 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR1 112/4885LPAR3 88/4885LPAR2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.